With a strong background in research and development, HempFusion is at the forefront of health and wellness in the rapidly growing CBD industry. Positioned for growth, the company distributes its family of brands to approximately 4,000 retailers across 47 US states, with plans for further international expansion.
In 2020, the company began conducting the Human Safety Study for liver toxicology and completed the NOAEL Safety Review for all topicals with Self GRAS Affirmation pending. They currently have 30 products under development, including additional OTC Drug Listed Ingestibles.
HempFusion is one of the few companies marketing FDA Drug Listed Topicals in compliance with all FDA regulations. Understanding the uncertainties of an emerging industry like CBD, HempFusion is working with twelve other CBD companies to conduct a study addressing FDA concerns regarding CBD products and human safety.
Invested heavily in regulatory compliance, HempFusion prioritizes safety, quality and consistency while aiming to exceed the high standard required by retailers and consumers. This is demonstrated in the company’s U.S. Hemp Authority Certification and status as a board member of the U.S. Hemp Roundtable, an organization committed to advancing safe hemp and CBD products.
The company’s rigid approach to regulatory compliance and best practices has favorably positioned them to enter major retail, food and drug markets that are not open to other CBD companies.
With an international expansion in their sights, HempFusion CBD and Probulin Probiotic product lines are projected to be sold across Europe, distributing to Ireland and the UK first. Additionally, the company already has purchase orders for Probulin Probiotics in the Middle East, South Korea, China, Mexico, and India.
In terms of domestic prospects, the company is well on their way to getting picked up by other major vendors and has their sights on becoming a top brand in the U.S. With the recent partnership with pro snowboarder and filmmaker Travis Rice, they hope to see more brand recognition amongst target audiences. The significant time and capital invested in HempFusion’s compliance provide the company with a competitive advantage in the expanding CBD sector, which is projected to reach $16.8 billion by 2025.
As of June 2020, HempFusion Wellness reported 1,750 shareholders and $18.3 million in cash with no debt. With the second-largest cash position in the sector, the company is gearing up for a direct IPO onto the Toronto Stock Exchange senior board, where it has reserved ticker symbol CBD.U.
HempFusion’s management team holds extensive experience in public markets, finance, legal, CPG and M&A. This world-class leadership has been crucial in driving the company’s business plan forward and primes them to expand their strategic networks and revenue opportunities. Potential channels could include natural medicine, e-commerce, big box, convenience, doctor practitioner and healthcare.
HempFusion Wellness Company Highlights
- Premium wellness company focused on providing innovative and diversified proprietary formulation using the power of whole-food hemp.
- Armed with world-class research and developmental processes, the company is prepared to market its premium CBD product lines across multiple distribution platforms.
- Offers a wide variety of CBD products that contain a broad spectrum of panoramic hemp extract, including liquids/tinctures, capsules, travel pouches and OTC topical products.
- Key partnerships with Verdant Oasis and Probulin Probiotics Co. has strategically positioned the company for international expansion into European markets and medicinal distribution networks.
- As of June 2020, HempFusion Wellness holds the second-largest cash position in the CBD sector, with over $18.3 million in cash and an estimated 1,750 shareholders.
- In May 2021, the company entered into a Purchase Agreement to acquire 100 percent interest in APCNA Holdings LLC (“Apothecanna”), a pioneer in cannabis-powered body care and topicals and an industry leader in the development of innovative, all-natural CBD products.
- Hempfusion completed the acquisition of Sagely Enterprises Inc. (“Sagely Naturals”), a leader in premium CBD products with mass distribution in more than 14,000 retailers nationwide.
- Alibaba Group Holding’s Tmall Global (“Tmall”) received conditional approval to launch HempFusion’s CBD products on Tmall, the world’s largest cross border online marketplace.
Get access to more exclusive Life Science Stock profiles here.
View original content to download multimedia: https://www.newswire.ca/en/releases/archive/January2021/22/c8250.html 